UC scientists develop CRISPR-engineered stem cell models
Recently, researchers at the University of California San Diego School of Medicine used genetically engineered human pluripotent stem cells to create a new type of cancer model for studying, in vivo, how glioblastoma develops and changes over time.
Co-senior author Dr. Frank B. Furnari said: "We have developed a CRISPR-engineered stem cell model with tumor-associated gene mutations in glioblastoma. Cells carrying these mutations essentially have all the characteristics of patient-derived tumors, including extrachromosomal DNA amplification."
In an article recently published in Nature Communications, the researchers used CRISPR editing technology to introduce targeted mutations in an otherwise normal genome, thereby creating genetic variants that can promote tumor development. The engineered tumor cells behaved very similarly to grade 4 glioma in terms of behavior, pathology, transcriptomic signatures and the evolution of genetic mutations.
Co-senior author Gene W. Yeo said: "The addition of single-cell RNA sequencing and computational tools allows us to truly assess tumor heterogeneity in vivo through big data analysis."
Existing mouse models can be used to test anticancer drugs against specific types of mutations, but cannot be applied to all tumor types. The authors believe this new modeling system provides a new platform for standardized research on tumor biology and evolution.
Yeo said: "We can now predict through testing which mutations really drive tumor initiation, and how they become invasive." Furnari said the model well mimics the previously observed phenomenon of tumor cell heterogeneity, making it the best choice for screening tumor evolution characteristics and seeking treatment options based on genetics. (Source: 生物谷. Information source: Stem cells, CRISPR and gene sequencing technology are basis of new brain cancer model. Original source: Koga, T et al. Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells. Nat Commun 11, 550 (2020). doi.org/10.1038/s41467-020-14312-1)
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.